Gregg Daniel Fine
44 works · 22,701 citations · h-index 28
Top works
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
- A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.
- Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
- Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).
- Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
- Abstract LB-288: A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.
- A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies
- Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.
- Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC).
- Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors.
- CD4 ligand IL-16 inhibits the mixed lymphocyte reaction
- IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation
- Abstract B001: Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab